Polina A. Demina

Associate
Full contact info

Passions

Hiking

Paddleboarding

Star Trek: TNG

Experience

Morphimmune Announces Merger With Immunome and $125 Million Private Investment

July 5, 2023

Cooley advised Morphimmune, a private biotechnology company, in its definitive merger agreement with Immunome and $125 million private investment.

Read more

Related contacts

Tom Coll
Partner, San Diego
Barbara Borden
Partner, San Diego
Carlos Ramirez
Partner, San Diego
Dylan Kornbluth
Associate, San Diego
Polina A. Demina
Associate, New York
Melissa Meza
Associate, San Diego
Kyrsten Lundh
Associate, San Diego
Daniel Gillon
Associate, San Diego
Nyron J. Persaud
Partner, New York
Todd Gluth
Partner, San Diego
Kay Chandler
Partner, San Diego
Ross Eberly
Partner, Los Angeles Santa Monica
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Sharon Connaughton
Special Counsel, Washington DC
Ajay Athavale
Associate, San Francisco
Joe Mandry
Associate, San Diego
Nathaniel Hearn Jr.
Associate, New York
Terren O'Connor
Associate, San Diego
Daniel Lac
Associate, San Diego
Eileen Leman
Associate, Los Angeles Downtown

Related Practices & Industries

Sol de Janeiro Sells Majority Stake to the L'Occitane Group

November 16, 2021

Cooley advised Sol de Janeiro, an innovative leader in the global prestige body care market, on its sale of a majority stake to The L’Occitane Group, an international group that manufactures and retails beauty and well-being products that are rich in natural and organic ingredients. Partner David Silverman led the team advising Sol de Janeiro.

Read more

Related contacts

David Silverman
Partner, New York
Mor Agam
Associate, New York
Polina A. Demina
Associate, New York
Stephanie Gentile
Partner, New York
Liza Hadley
Associate, Boston
Len Jacoby
Partner, New York
Nicollette R. Kirby
Associate, Washington DC
Patrick Sharma
Associate, Los Angeles Santa Monica

Related Practices & Industries

Five Prime Therapeutics Agrees to Sell to Amgen for $1.9 Billion

April 27, 2021

Cooley advised Five Prime Therapeutics, a publicly traded clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, on its agreement to sell to Amgen in an all-cash transaction with an equity value of approximately $1.9 billion. Partners Jamie Leigh, Ian Nussbaum and Laura Berezin led the Cooley team advising Five Prime.

Read more

Related contacts

Jamie Leigh
Partner, San Francisco
Laura Berezin
Partner, Palo Alto
Jaime L. Chase
Partner, Washington DC
Polina A. Demina
Associate, New York
Wendy Brenner
Partner, Palo Alto
Natasha Leskovsek
Of Counsel, Washington DC
Howard Morse
Partner, Washington DC
David Burns
Special Counsel, Washington DC
Amanda Pacheco
Associate, Palo Alto
Barbara Mirza
Partner, Los Angeles Santa Monica

Related Practices & Industries

Rankings & accolades

Super Lawyers: Rising Star (2019 – 2022)

The Investment Management Consultants Association's Richard J. Davis Ethics, Legal, Regulatory Insight Award (2015)